1.Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. 2004 The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 44(4):398-404
2. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008 Nov;52(5):818-27
3. Damasceno A, Azevedo A, Silva-Matos C, Prista A, Diogo D, Lunet N. Hypertension prevalence, awareness, treatment, and control in Mozambique: urban/rural gap during epidemiological transition. Hypertension. 2009 Jul;54(1):77-83
4.Hemmelgarn BR, McAllister FA, Myers MG, et al. 2005 The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1-blood pressure measurement, diagnosis, and assessment of risk. Can J Cardiol 21:645-656
5. Brady TM & Feld LG 2009 Pediatric approach to hypertension. Semin Nephrol 29
379-388.
6. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD004349.
7. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006 Dec 5;48(11):2293-300
8. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. American Heart Association Professional Education Committee 2008 Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008 Jun;51(6):1403-19
9. Plouin PF, Degoulet P, Tugayé A, Ducrocq MB, Ménard J. Screening for pheochromocytoma: in which hypertensive patients ? A semiological study of 2,585 patients including 11 with pheochromocytoma. Nouv Presse Med. 1981 Mar 7;10(11):869-72.
10. Walther MM et al., Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 162: 659-664
11. Otsuka F, Ogura T, Nakagawa M, Hayakawa N, Kataoka H, Oishi T, Makino H. Normotensive bilateral pheochromocytoma with Lindau disease. Endocr J. 1996 Dec;43(6):719-23
12. Agarwal A, Gupta S, Mishra AK, Singh N, Mishra SK. Normotensive pheochromocytoma: institutional experience. World J Surg. 2005 Sep;29(9):1185-8.
13. Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, Ventz M, Beuschlein F, Reincke M, Reisch N, Quinkler M. Frequent incidental discovery of pheochromocytoma: data from a German cohort of 201 pheochromocytomas. Eur J Endocrinol. 2009 Aug;161(2):355-61.
14. Bhansali A, Rajput R, Behra A, Rao KL, Khandelwal N, Radotra BD. Childhood sporadic pheochromocytoma: clinical profile and outcome in 19 patients. J Pediatr Endocrinol Metab. 2006 May;19(5):749-56.
15.Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM &
Montori VM 2008 The diagnosis of Cushing’s syndrome: an Endocrine Society
Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 93
1526-1540.
16. Koch CA. Adrenal cortex, physiology. In: Martini L (ed.): Encyclopedia of Endocrinology and Endocrine Diseases. Academic Press, San Diego, CA, 2004
17. Vasan RS, Evans JC, Larson MG, et al. 2004 Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351:33-41
18. Gordon RD, Stowasser M, Tunny TJ, et al. 1994 High incidence of primary hyperaldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21:315-318
19. Fardella CE, Mosso L, Gomez-Sanchez CE, et al. 2000 Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85:1863-1867
20. Mulatero P, Milan A, Fallo F, et al. 2006 Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 91(7):2618-23
21. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr & Montori VM; Endocrine Society 2008 Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 93 3266-3281.
22. Williams JS, Williams GH, Raji A, et al. 2006 Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalemia. J Hum Hypertens 20:129-136
23. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008;371:1921-1926
24. Stowasser M, Gordon RD. 2000 Primary aldosteronism: learning from the study of familial varieties. J Hypertension 18:1165-1176
25. Streeten DH, Tomycz N, Anderson GH. 1979 Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med 67:403-413
26. Seiler L, Rump LC, Schulte-Monting J, et al. 2004 Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 150:329-337
27. Mattson C, Young WF Jr. 2006 Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2:198-208
28. Giacchetti G, Ronconi V, Lucarelli G, et al. 2006 Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 24:737-745
29. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Endres S, Quinkler M; Participants of the German Conn's Registry. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s registry. J Clin Endocrinol Metab 2009;94:1125-1130
30. Stowasser M 2009 Update in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 94 3623-3630.
31. Ulick S, Blumenfeld JD, Atlas SA, et al. 1992 The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism. J Clin Endocrinol Metab 76:873-878
32. Thompson GB, Young WF Jr. 2006 Selective use of adrenal venous sampling in the lateralization of aldosterone-producing adenomas. World J Surg 886-887
33. Young WF, Stanson AW, Thompson GB, et al. 2004 Role of adrenal venous sampling in primary aldosteronism. Surgery 136:1227-1235
34. Toniato A, Bernante P, Rossi GP, Pelizzo MR. 2006 The role of adrenal venous sampling in the surgical management of primary aldosteronism. World J Surg 30:624-627
35. Gordon RD, Stowasser M. 1998 Familial forms broaden the horizons for primary aldosteronism. Trends Endocrinol Metab 9:220-223
36. Stowasser M, Gordon RD. 2006 Monogenic mineralocorticoid hypertension. Best Pract Res Clin Endocrinol Metab 20:401-420
37. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008 Aug;93(8):3117-23
38. Mulatero P. A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III. J Clin Endocrinol Metab. 2008 Aug;93(8):2972-4.
39. Sutherland DJ, Ruse JL, Laidlaw JC. 1966 Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 95:1109-1119
40. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. 1992 A chimeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355:262-265
41. Litchfield WR, Anderson BF, Weiss RJ, et al. 1998 Intracranial aneurysms and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31:445-450
42. Litchfield WR, New MI, Coolidge C, et al. 1997 Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 82:3570-3573
43. Grim CE, Weinberger MH. 1980 Familial, dexamethasone-suppressible, normokalemic hyperaldosteronism. Pediatrics 65:597-604
44. Lafferty AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard P, Gordon RD, Stratakis CA. 2000 A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7p22. J Med Genet 37:831-835
45. Stowasser M, Gordon RD. 2006 Aldosterone assays: an urgent need for improvement. Clin Chem 52:1640-1642
46. Schirpenbach C, Seiler L, Maser-Gluth C, et al. 2006 Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassay with and without extraction steps. Clin Chem 52:1749-1755
47. Kratzsch J, Wende D, Thiery J, Koch CA. Basal aldosterone-renin-ratio and aldosterone levels in healthy adults during the saline load test. Clin Chem Lab Med 2007;45-9:A114-A115 (German dissertation, D. Wende, 2008)
48. Weinberger MH, Fineberg NS. 1993 The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Int Med 153:2125-2129
49. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007;66:607-618
50. Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, Deinum J. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009 Sep 1;151(5):329-37
51. Hedeland H, Ostberg G, Hokfelt B. On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes. Acta Med Scand 1968;184:211-214
52. Sukor N, Gordon RD, Ku YK, Jones M & Stowasser M 2009 Role of Unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. Journal of Clinical Endocrinology and Metabolism 94 2437-2445.
53. Letavernier E, Peyrard S, Amar L, Zinzindohoue F, Fiquet B & Plouin PF 2009 Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. Journal of Hypertension 26 1816-1823.
54. Young WF. 2002 Primary aldosteronism. Ann NY Acad Sci 970:61-76
55. Meyer A, Brabant G, Behrend M. 2005 Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surg 29:155-159
56. Rossi GP. 2006 Surgically correctable hypertension caused by primary aldosteronism. Best Pract Res Clin Endocrinol Metab 20:385-400
57. Magni P, Motta M. 2005 Aldosterone receptor antagonists: biology and novel therapeutic applications. Curr Hypertens Rep 7:206-211
58. Gordon RD, Laragh JH, Funder JW. 2005 Low renin hypertensive states: perspectives, unsolved problems, future research. Trends Endocrinol Metab 16:108-113
59. Karagiannis A, Tziomalos K, Kakafika A, et al. 2007 Eplerenone relieves spironolactone-induced painful gynecomastia in a patient with primary aldosteronism. Nephrol Dial Transplant 22(1):293
60. Jansen PM, van den Meiracker AH & Jan Danswer AH 2009 Aldosterone synthase
inhibitors: pharmacological and clinical aspects. Curr Opin Investig Drugs 10 319-326.
61. Gomez-Sanchez EP. MR, tying down a promiscuous receptor. Exp Physiol. 2009
62. Catena C, Lapenna R, Baroselli S, et al. 2006 Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91:3457-3463
63. Matrozova J, Streichen O, Amar L, Zacharieva S, Jeunemaitre , Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009; 53:601-610
64. Sowers J, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009;150:776-783
65. Koch CA, Vortmeyer AO, Zhuang Z, Brouwers FM, Pacak K. 2002 New insights into the genetics of familial chromaffin cell tumors. Ann NY Acad Sci 970:11-28
66. Brown MJ, Grosssman AB, Bornstein SR. Pheochromocytoma. Horm Metab Res 2009;41:655-657
67. Neumann HPH, et al. 2002 Germline mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1486-1488
68. Koch CA, Pacak K, Chrousos GP. 2002 The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 87(12):5367-84
69. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. 2005 Phaeochromocytoma. Lancet 366:665-675
70. Reisch N, Peczkowska M, Januszewicz A, Neumann HPH. 2006 Pheochromocytoma: presentation, diagnosis, and treatment. J Hypertens 24:2331-2339
71. Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann P, Brauckhoff M, Mussig K, Muresan M, Schaffler A, Reisch N, Schott M, Fassnacht M, Opocher G, Klose S, Fottner C, Forrer F, Plockinger U, Petersenn S, Zabolotny D, Kollukch O, Yaremchuk S, Januszewicz A, Walz M, Eng C & Neumann HPH 2009 Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clinical Cancer Res 15 6378-6385.
72. Jiménez C, Cote G, Arnold A, Gagel RF. Should patients with apparently sporadic pheochromocytoma or paragangliomas be screened for hereditary syndromes ? J Clin Endocrinol Metab. 2006 Aug;91(8):2851-8.
73. Eisenhofer G, Walther MM, Huynh TT, et al. 2001 Pheochromoytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 86:1999-2008
74. Bravo EL, Tagle R. 2003 Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24:539-553
75. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic nerve ablation for uncontrolled hypertension.N Engl J Med. 2009 Aug 27;361(9):932-4
76. Lenders JW, Pacak K, Walther MM, et al. 2002 Biochemical diagnosis of pheochromocytoma: which test is best ? JAMA 287:1427-1434
77. Unger N, Pitt C, Schmidt IL, et al. 2006 Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 154:409-417
78. Miehle K, Kratzsch J, Lenders JW, Kluge R, Paschke R, Koch CA. 2005 Adrenal incidentaloma diagnosed as pheochromocytoma by plasma chromogranin A and plasma metanephrines. J Endocrinol Invest 28:1040-1042
79. Grossrubatscher E, Dalino P, Vignati F, et al. 2006 The role of chromogranin A in the management of patients with pheochromocytoma. Clin Endocrinol 65:287-293
80. Giovanella L, Squin N, Ghelfo A, Ceriani L. 2006 Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. Q J Nucl Med Mol Imaging 50:344-347
81. Singh RJ, Eisenhofer G. High-throughput, automated, and accurate biochemical screening for pheochromocytoma: are we there yet ? Clin Chem 2007;53:1565-1567
82. Koch CA, Rodbard JS, Brouwers FM, Eisenhofer G, Pacak K. 2003 Hypotension in a woman with a metastatic dopamine-secreting carotid body tumor. Endocr Pract 9:310-314
83. Eisenhofer G, Huysmans F, Pacak K, Walther MM, Sweep FC, Lenders JW. Plasma metanephrines in renal failure. Kidney Int. 2005 Feb;67(2):668-77
84. Majumdar S, Friedrich CA, Koch CA, Megason GC, Fraktin JD, Moll GW. Compound heterozygous mutation with a novel splice donor region DNA sequence variant in the succinate dehydrogenase subunit B gene in a boy with malignant paraganglioma. Pediatr Blood Cancer 2009
85. Timmers HJ, Gimenez-Roqueplo AP, Mannelli M, Pacak K. Clinical aspects of SHDx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2009 Jun;16(2):391-400
86. Timmers HJ, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, Ling A, Adams KT, Pacak K. Use of 6-18F-fluorodopamine positron emission tomography as first-line investigation for the diagnosis and localization of non-metastatic and metatatic pheochromocytoma. Clin Endocrinol (Oxf). 2009 Jul;71(1):11-7
87. Bhatia KS, Ismail MM, Sahdev A, Rockall AG, Hogarth K, Canizales A, Avril N, Monson JP, Grossman AB, Reznek RH. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal pheochromocytoma: CT and MRI correlation. Clin Endocrinol (Oxf). 2008 Aug;69(2):181-8.
88. Koch CA. Should 123I-MIBG scintigraphy be part of the workup for pheochromocytomas? Nat Clin Pract Endocrinol Metab. 2009 Feb;5(2):76-7
89. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med. 2008 Aug;49(8):1232-7
90. Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, Knox JJ. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 2009;94:5-9
91. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier NDm, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. Use of tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 2009;94:386-391
92. Neumann HP, Vortmeyer A, Schmidt D, Werner M, Erlic Z, Cascon A, Bausch B, Januszewicz A, Eng C. Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med. 2007 Sep 27;357(13):1311-5
93. Nebesio TD, Eugster EA 2006 Observation of hypertension in children with 21-
hydroxylase deficiency: a preliminary report. Endocrine 30 279-282.
94. Kim MS, Merke DP. Cardiovascular disease risk in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Semin Reprod Med. 2009 Jul;27(4):316-21.
95. Zachmann M, Tassinari D, Prader A. 1983 Clinical and biochemical variabilitiy of congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency. J Endocrinol Metab 56:222-229
96. New MI, Geller DS, Fallo F, Wilson RC. 2005 Monogenic low rennin hypertension. Trends Endocrinol Metab 16:92-97
97. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003;349:776-788
98. Kacem M, Moussa A, Khochtali I, Nabouli R, Morel Y & Zakhama A 2009 Bilateral
Adrenalectomy for severe hypertension in congenital adrenal hyperplasia due to 11beta
Hydroxylase deficiency: long term follow-up. Annals of Endocrinology 70 113-118.
99. Wong SL, Shu SG, Tsai CR. 2006 Seventeen alpha-hydroxylase deficiency. J Formos Med Assoc 105:177-181
100. Costa-Santos M, Kater CE, Auchus RJ, et al. 2004 Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J Clin Endocrinol Metab 89:49-60
101. Wong SL, Shu SG, Tsai CR. Seventeen alpha-hydroxylase deficiency. J Formos Med Assoc 2006;105:177-181
102. Lavery GG, Ronconi V, Draper N, et al. 2003 Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension 42:123-129
103. Carvajal CA, Gonzales AA, Romero DG, Gonzales A, et al. 2003 Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 88:2501-2507
104. Palermo M, Quinkler M, Stewart PM. 2004 Apparent mineralocorticoid excess syndrome: an overview. Arq Bras Endocrinol Metab 48:687-696
105. Lin-Su K, Zhou P, Arora N, et al. 2004 In vitro expression studies of a novel mutation delta299 in a patient affected with apparent mineralocorticoid excess. J Clin Endocrinol Metab 89:2024-2027
106. New MI, Levine LS, Biglieri EG, Paeira J, Ulick S. 1977 Evidence for an unidentified ACTH-induced steroid hormone causing hypertension. J Clin Endocrinol Metab 44:924-933
107. Wilson RC, Krozowski ZS, Li K, et al. 1995 A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80:2263-2266
108. Stewart PM, Corrie JE, Shackleton CH, Edwards CR. 1988 Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest 82:340-349
109. Arriza JL, Weinberger C, Cerelli G, Glaser TM, et al. 1987 Cloning of the human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268-275
110. Funder JW, Pearce PT, Smith R, Smith AI. 1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor mediated. Science 242:583-585
111. Heilmann P, Buchheim E, Wacker J, Ziegler R. 2001 Alteration of the activity of the 11beta-hydroxysteroid dehydrogenase in pregnancy: relevance for the development of pregnancy-induced hypertension ? J Clin Endocrinol Metab 276:5222-5226
112. Quinkler M, Oelkers W, Diederich S. 2000 In vivo measurement of renal 11beta-hydroxysteroid dehydrogenase type 2 activity. J Clin Endocrinol Metab 85:4921-4922
113. Geller DS, Farhi A, Pinkerton N, et al. 2000 Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289:119-123
114. Liddle GW, Bledsoe T, Coppage WS Jr. 1963 A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 76:199-213
115. Gordon RD, Geddes RA, Pawsey CG, O’Halloran MW. 1970 Hypertension and severe hyperkalemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 19:287-294
116. Geller DS. 2005 Mineralocorticoid resistance. Clin Endocrinol 62:513-520
117. Klemm SA, Gordon RD, Tunny TJ, Thompson RE 1991 The syndrome of hypertension and hyperkalemia with normal GFR (Gordon’s syndrome): is there increased proximal sodium reabsorption ? Clin Invest Med 14:551-558
118. Wilson FH, Disse-Nicodeme S, Choate KA, et al. 2001 Human hypertension caused by mutations in WNK kinases. Science 293:11-14
119. Mansfield TA, Simon DB, Farfel Z, et al. 1997 Multilocus linkage of familial hyperkalemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p-q21. Nat Genet 16:202-205
120. Kahle KT, Wilson FH, Leng Q, et al. 2003 WNK4 regulates the balance between renal NaCl reabsorption and K secretion. Nat Genet 35:372-376
121. Xie J, Craig L, Cobb MH, Huang CL. 2006 Role of with-no-lysine (K) kinases in the pathogenesis of Gordon’s syndrome. Pediatr Nephrol 21(9):1231-6
122. Tobin MD, Raleigh SM, Newhouse S, et al. 2005 Association of WNK1 gene polymorphisms and haplotypes with ambulatory blood pressure in the general population. Circulation 112:3423-3429
123. Wofford MR, King DS, Harrel TK. 2006 Drug-induced metabolic syndrome. J Clin Hypertens 8:114-119
124. Haffner SM, Ruilope L, Dahlof B, et al. 2006 Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials. J Cardiovasc Pharmacol 47:469-475
125. Saad MF, Rewers M, Selby J, et al. Insulin resistance and hypertension: the insulin resistance atherosclerosis study. Hypertension 43:1324-1331
126. Steinberg HO, Baron AD. Vascular function, insulin resistance, and fatty acids. Diabetologia. 2002 May;45(5):623-34.
127. Ferrannini E, Buzzigoli G, Bonadonna R, et al. 1987 Insulin resistance in essential hypertension. N Engl J Med 317:350-357
128. Wofford MR, Hall JE. 2004 Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 10:3621-3637
129. Levy J, Gavin JR III, Hammermann MR, et al. 1986 Ca- and Mg-ATPase activity in kidney basolateral membrane in non insulin dependent diabetic rats: effect of insulin. Diabetes 35:899-905
130. Dluhy RG, Lawrence JE, Williams GH. Endocrine Hypertension. In: Williams Textbook of Endocrinology, 10th edition, Saunders, 2002, pages 552-585
131. Ronti T, Lupattelli G, Mannarino E. 2006 The endocrine function of adipose tissue:an update. Clin Endocrinol 64:355-365
132. Bogaert YE & Linas S 2009 The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol 5 101-111.
133. Graessler J, Schwudke D, Schwarz PE, Herzog R, Shevchenko A, Bornstein SR. Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS One. 2009 Jul 15;4(7):e6261
134. McCarron DA, Pingree PA, Rubin RJ, Gaucher SM, Molitch M, Krutzik S. Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinary calcium leak. Hypertension. 1980 Mar-Apr;2(2):162-8.
135. Bukoski RD, Ishibashi K, Bian K. 1995 Vascular actions of the calcium regulating hormones. Semin Nephrol 15:536-549
136. Hulter HN, Melby JC, Peterson JC & Cooke CR 1986 Chronic continuous PTH infusion results in hypertension in normal subjects. Journal of Clinical Hypertension 2 360-370.
137. Bucher HC, Cook RJ, Guyatt GH, et al. 1996 Effects of dietary calcium supplementation in blood pressure: a metaanalysis of randomized controlled trials. JAMA 275:1016-1022
138. Allender PS, Cutler JA, Follmann D, et al. 1996 Dietary calcium and blood pressure: a metaanalysis of randomized clinical trials. Ann Intern Med 124:825-831
139. Silverberg SJ. 2002 Non-classical target organs in primary hyperparathyroidism. J Bone Miner Res Supp;2:N117-25
140. Bollerslev J, Rosen T, Mollerup CL, Nordenstrom J, Baranowski M, Franco C, Pernow Y, Isaksen GA, Godang K, Ueland T et al; SIPH Study Group 2009 Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 94 2255-2261.
141. Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Tørring O, Varhaug JE, Baranowski M, Aanderud S, Franco C, Freyschuss B, Isaksen GA, Ueland T, Rosen T. Medical observation, compared with parathyroidectomy for asymptomatic hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007 May;92(5):1687-92.
142. Puepet FH, Agaba EI, Chuhwak EK & Ugoya SO 2008 Primary hyperparathyroidism presenting with severe hypertension in a middle aged Nigerian—a case report. Nigerian Postgraduate Medical Journal 15 58-60.
143. Rubin MR, Maurer MS, McMahon DJ, et al. 2005 Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 90:3326-3330
144. Walker MD, Fleischer J, Rundek T, McMahon DJ, Homma S, Sacco R, Silverberg SJ. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab. 2009 Oct;94(10):3849-56
145. Ekmekci A, Abaci N, Ozbey NC, Agayev A, Aksakal N, Oflaz H, Erginel-Unaltuna N & Erbil Y 2009 Endothelial Function and Endothelial Nitric Oxide Synthase Intron 4a/b Polymorphism in Primary Hyperparathyroidism. Journal of Endocrinological Investigation
146. Bilezikian JP, Khan AA & Potts JT Jr; Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism 2009 Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. Journal of Clinical Endocrinology and Metabolism 94 335-339.
147. Savage M, Lienhardt A, Lebrethon M, et al. 2001 Cushing’s disease in childhood : presentation, investigation, treatment and long-term outcome. Horm Res 55:24-30
148. Magiakou M, Mastorakos G, Oldfield EH, et al. 1994 Cushing’s syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med 331:629-636
149. Lodish MB, Sinaii N, Patronas N, Batista DL, Keil M, Samuel J, Moran J, Verma S, Popovic J, Stratakis CA. Blood pressure in pediatric patients with Cushing syndrome. J Clin Endocrinol Metab. 2009 Jun;94(6):2002-8.
150. Magiakou MA, Mastorakos G, Zachman K, Chrousos GP. Blood pressure in children and adolescents with Cushing’s syndrome before and after surgical care. J Clin Endocrinol Metab. 1997 Jun;82(6):1734-8.
151. Zacharieva S, Orbetzova M, Stoynev A, et al. 2004 Circadian blood pressure profile in patients with Cushing’s syndrome before and after treatment. J Endocrinol Invest 27:924-930
152. Baid S, Nieman LK. 2004 Glucocorticoid excess and hypertension. Curr Hypertens Rep 6:493-499
153. Torpy DJ, Mullen N, Ilias I, Nieman LK. 2002 Association of hypertension and hypokalemia with Cushing’s syndrome caused by ectopic ACTH secretion. Ann NY Acad Sci 970:134-144
154. Mantero F, Boscaro M. 1992 Glucocorticoid-dependent hypertension. J Steroid Biochem Mol Biol 43:409-413
155. Pirpiris M, Yeung S, Dewar E, et al. 1993 Hydrocortisone-induced hypertension in men. The role of cardiac output. Am J Hypertension 6:287-294
156. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. 2006 Cushing’s syndrome. Lancet 367:1605-1617
157. Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, Fishman E, Kharlip J; American Association of Clinical Endocrinologists; American Association of Endocrine Surgeons. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations. Endocr Pract. 2009 Jul-Aug;15(5):450-3.
158. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F & Ballotta E 2009
Surgical versus conservative management for subclinical Cushing syndrome in adrenal
incidentalomas: a prospective randomized study. Annals of Surgery 249 388-391.
159. Kino T, Vottero A, Charmandari E, Chrousos GP. 2002 Familial/sporadic glucocorticoid resistance syndrome and hypertension. Ann NY Acad Sci 970:101-111
160. Chrousos GP, Vingerhoeds A, Brandon D, et al. 1982 Primary cortisol resistance. J Clin Invest 69:1261-1269
161. Charmandari E, Kino T, Ichijo T & Chrousos GP 2008 Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. Journal of Clinical Endocrinology and Metabolism 93 1563-1572.
162. Danzi S, Klein I. 2003 Thyroid hormone and blood pressure regulation. Curr Hypertens Rep 5:513-520
163. Prisant LM, Gujral JS, Mulloy AL. 2006 Hyperthyroidism: a secondary cause of isolated systolic hypertension. J Clin Hypertens 8:596-599
164. Klein I. 1990 Thyroid hormone and the cardiovascular system. Am J Med 88:631-637
165. Woeber KA. 1992 Thyrotoxicosis and the heart. N Engl J Med 327:94-98
166. Fountoulakis S, Tsatsoulis A. Molecular genetic aspects and pathophysiology of endocrine hypertension. Hormones (Athens). 2006 Apr-Jun;5(2):90-106
167. Iglesias P, Acosta M, Sanchez R, Fernandez-Reyes MJ, Mon C & Diez JJ 2005
Ambulatory blood pressure monitoring in patients with hyperthyroidism before and
after control of thyroid function. Clinical Endocrinology 63 66-72.
168. Tamer I, Sargin M, Sargin H, et al. 2005 The evaluation of left ventricular hypertrophy in hypertensive patients with subclinical hyperthyroidism. Endocr J 52:421-425
169. Volzke H, Alte D, Dorr M, et al. 2006 The association between subclinical hyperthyroidism and blood pressure in a population-based study. J Hypertens 24:1947-1953
170. Biondi B, Klein I. 2004 Hypothyroidism as a risk factor for cardiovascular disease. Endocrine 24:1-13
171. Kotsis V, Alevizake M, Stabouli S, Pitiriga V, Rizos Z, Sion M & Zakopoulos N 2007
Hypertension and hypothyroidism: results from an ambulatory blood pressure monitoring study. Journal of Hypertension 25 993-999.
172. Streeten DHP, Anderson GH Jr, Howland T, et al. 1988 Effects of thyroid function on blood pressure: recognition of hypothyroid hypertension. Hypertension 11:78-83
173. Iqbal A, Figenschau Y, Jorde R. 2006 Blood pressure in relation to serum thyrotropin : the Tromso study. J Hum Hypertens 20(12):932-6
174. Walsh JP, Bremner AP, Bulsara MK, et al. 2006 Subclinical thyroid dysfunction and blood pressure: a community-based study. Clin Endocrinol 65:486-491
175. Biondi B & Cooper DS 2008 The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews 29 76-131.
176. Duan Y, Wang X, Peng W, Feng Y, Tang W, Wu X, Mao X, Bo R, Li W, Chen J, Qin Y, Liu C & Liu C 2009 Gender-specific associations between subclinical hypothyroidism and blood pressure in Chinese adults. Endocrine 2009
177. Vitale G, Pivonello R, Auriemma RS, et al. 2005 Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol 63:470-476
178. Bondanelli M, Amrosio MR, Degliuberti EC. 2001 Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 4:239-249
179. Colao A, Ferone D, Marzullo P, et al. 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102-152
180. Rizzoni D, Porteri E, Giustina A, De Ciuceis C, Sleiman I, Boari GE, Castellano M, Muiesan ML, Bonadonna S, Burattin A, Cerudelli B, Agabiti-Rosei E. Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries. Hypertension. 2004 Mar;43(3):561-5.
181. Falkheden T, SjÃgren B. 1964 Extracellular fluid volume and renal function in pituitary insufficiency and acromegaly. Acta Endocrinol 46:80-88
182. Lombardi G, Galdiero M, Auriemma RS, et al. 2006 Acromegaly and the cardiovascular system. Neuroendocrinology 83:211-217
183. Mulatero P, Veglio F, Maffei P, Bondanelli M, Bovio S, Daffara F, Leotta G, Angeli A, Calvo C, Martini C, degli Uberti EC, Terzolo M. CYP11B2-344T/C gene polymorphism and blood pressure in patients with acromegaly. J Clin Endocrinol Metab. 2006 Dec;91(12):5008-12
184. Bielohuby M, Roemmler J, Manolopoulou J, Johnsen I, Sawitzky M, Schopohl J,
Reincke M, Wolf E, Hoeflich A & Bidlingmaier M 2009 Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice. Exp Biol Med (Maywood). 2009 Aug;234(8):1002-9.
185. Delaroudis SP, Efstathiadou ZA, Koukoulis GN, Kita MD, Farmakiotis D, Dara OG, Goulis DG, Makedou A, Makris P, Slavakis A et al. 2008 Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clinical Endocrinology 69 279-284.
186. Colao A, Terzolo M, Bondanelli M, Galderisi M, Vitale G, Reimondo G, Ambrosio MR, Pivonello R, Lombardi G, Angeli A, degli Uberti EC. GH and IGF-1 excess control contributes to blood pressure control: results of an observational, retrospective, multicenter study in 105 hypertensive acromegalic patients on hypertensive treatment. Clin Endocrinol (Oxf). 2008 Oct;69(4):613-20.
187. Ullah MI, Uwaifo GI, Nicholas WC, Koch CA. Does vitamin D deficiency cause hypertension ? Current evidence from clinical studies and potential mechanisms. International J Endocrinol 2009
188. Judd SE, Tangpricha V. Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci. 2009 Jul;338(1):40-4
189. Kazi M, Geraci SA, Koch CA. Considerations for the diagnosis and treatment of testosterone deficiency in elderly men. Am J Med. 2007 Oct;120(10):835-40.
190. Shabsigh R, Arver S, Channer KS, Eardley I, Fabbri A, Gooren L, Heufelder A, Jones H, Meryn S, Zitzmann M. The triad of erectile dysfunction, hypogonadism, and the metabolic syndrome. Int J Clin Pract. 2008 May;62(5):791-8.
191. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006 Nov;91(11):4335-43.
192. Zitzmann M. Effects of testosterone replacement and its pharmacogenetics on physical performance and metabolism. Asian J Androl. 2008 May;10(3):364-72.
193. Haring R, Völzke H, Felix SB, Schipf S, Dörr M, Rosskopf D, Nauck M, Schöfl C, Wallaschofski H. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes. 2009 Sep;58(9):2027-31
194. Heufelder AE, Saad F, Bunck MC, Gooren LJ. 52-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009
195. Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S, Kawakubo M, Stewart Y, Yarasheski KE, Ulloor J, Colletti P, Roubenoff R, Azen SP. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab. 2009 Jun;94(6):1991-2001
196. Widdowson WM, Gibney J. The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J Clin Endocrinol Metab. 2008 Nov;93(11):4413-7
197. Mekala KC, Tritos NA. Effects of recombinant human growth hormone therapy in obesity in adults: a metaanalysis. J Clin Endocrinol Metab. 2009 Jan;94(1):130-7
198. Bannink EM, van der Palen RL, Mulder PG, de Muinck Keizer-Schrama SM. Long-term follow-up of GH-treated girls with Turner syndrome: metabolic consequences. Horm Res. 2009;71(6):343-9.
199. Di Somma C, Pivonello R, Pizza G, De Rosa A, Lombardi G, Colao A, Savastano S. Prevalence of the metabolic syndrome in moderately severely obese subjects with and without growth hormone deficiency. J Endocrinol Invest. 2009
200. Russell M, Bredella M, Tsai P, Mendes N, Miller KK, Klibanski A, Misra M. Relative growth hormone deficiency and cortisol excess are associated with increased cardiovascular risk markers in obese adolescent girls. J Clin Endocrinol Metab. 2009 Aug;94(8):2864-71
201. Uwaifo GI, Melcescu E, McDonald A, Koch CA. A case of profound weight loss
secondary to use of phentermine. J Miss State Med Assoc 2009
202. Michailidou Z, Carter RN, Marshall E, Sutherland HG, Brownstein DG, Owen E, Cockett K, Kelly V, Ramage L, Al-Dujaili EAS, Ross M, Maraki I, Newton K, Holmes MC, Seckl JR, Morton NM, Kenyon CJ & Chapman KE Glucocorticoid receptor haploinsufficiency causes hypertension and attenuates hypothalamic-pituitary-adrenal axis and blood pressure adaptions to high-fat diet. FASEB J. 2008 Nov;22(11):3896-907.
203. Zhang J, Ge R, Matte-Martone C, Goodwin J, Shlomchik WD, Mamula MJ, Kooshkabadi A, Hardy MP & Geller D 2009 Characterization of a novel gain of function glucocorticoid receptor knock-in mouse. J Biol Chem 284 6249-6259.